Wittke R
Sports Medicine Institute, Bayreuth, Germany.
Sports Med. 1999 May;27(5):329-35. doi: 10.2165/00007256-199927050-00004.
To establish whether patients receiving the cholesterol synthesis enzyme inhibitor fluvastatin 20 mg/day could obtain an additional improvement in their lipid pattern as a result of physical endurance training.
This was an observational study using a before- and after-treatment comparison of fitness and lipid parameters in outpatients with dyslipidaemia who undertook an exercise programme with or without treatment with a lipid-lowering drug.
Participants were 18 sedentary [maximum oxygen uptake (VO2max) < 30 ml/kg bodyweight per minute] men (age range 38 to 65 years) with dyslipidaemia but without overt cardiovascular disease.
All participants undertook a 1-hour bout of endurance training twice a week for 3 months. The training involved a circuit using various ergometers, with continuous monitoring of pulse rate, at an exercise intensity of 2 to 3 mmol/L lactate. The control group (n = 6) received no drug treatment; they completed the training programme only. The pretreatment group (n = 6) comprised participants who had already been treated with fluvastatin 20 mg/day for at least 3 months before beginning the training programme. The treatment group (n = 6) received fluvastatin 20 mg/day from the beginning of the training programme. All participants were required to comply with the exercise programme and with a standardised carbohydrate-loaded diet together with restriction of alcohol consumption to a maximum of 20 ml/day.
In the control group, increased physical activity alone reduced serum triglyceride (TG) levels (-24.7%) and increased serum high density lipoprotein-cholesterol (HDL-C) levels (+19.3%). There was a smaller effect on serum low density lipoprotein-cholesterol (LDL-C) levels (-12.8%). Similar but smaller effects were observed in the pretreatment group (i.e. patients previously treated with fluvastatin): TG -12.88%, HDL-C +13.81%, LDL-C -8.7%. Marked changes were observed in the treatment group: TG -33.1%, HDL-C +34.7%, LDL-C -40.5%, total cholesterol -30.5%.
A reduction of serum LDL-C level in the target range of -30 to -40% cannot be achieved by this intensity of training alone. In combination with fluvastatin 20 mg/day, however, the positive effects on lipid metabolism are potentiated. Thus, treatment with fluvastatin combined with moderate endurance training is a rational mode of therapy, particularly in patients with a highly pathological lipid profile.
确定每日服用20毫克胆固醇合成酶抑制剂氟伐他汀的患者是否能因进行耐力训练而使其血脂状况得到进一步改善。
这是一项观察性研究,对血脂异常门诊患者在进行或未进行降脂药物治疗的情况下进行健身和血脂参数的治疗前后比较。
参与者为18名久坐不动的(最大摄氧量[VO2max]<每分钟30毫升/千克体重)男性(年龄范围38至65岁),患有血脂异常但无明显心血管疾病。
所有参与者每周进行两次为期3个月的1小时耐力训练。训练包括使用各种测力计的循环训练,持续监测脉搏率,运动强度为2至3毫摩尔/升乳酸。对照组(n = 6)未接受药物治疗;他们仅完成训练计划。预处理组(n = 6)由在开始训练计划前已接受每日20毫克氟伐他汀治疗至少3个月的参与者组成。治疗组(n = 6)从训练计划开始时接受每日20毫克氟伐他汀治疗。所有参与者均需遵守运动计划,并遵循标准化的高碳水化合物饮食,同时将酒精摄入量限制在每天最多20毫升。
在对照组中,仅增加体力活动即可降低血清甘油三酯(TG)水平(-24.7%)并提高血清高密度脂蛋白胆固醇(HDL-C)水平(+19.3%)。对血清低密度脂蛋白胆固醇(LDL-C)水平的影响较小(-12.8%)。在预处理组(即先前接受氟伐他汀治疗的患者)中观察到类似但较小的效果:TG -12.88%,HDL-C +13.81%,LDL-C -